GemPharmatech and Humlab Global Sign Strategic Agreement to Deliver Humanized Mouse Models for Improved Clinical Translation
GemPharmatech, an international provider of in vivo efficacy testing and genetically engineered animal models, and Humlab Global, a Singapore-based developer of humanized mouse models and translational research solutions, today announced the signing of an agreement for the global distribution of existing and novel humanized strains.
GemPharmatech, Leading Provider of Genetically Engineered Mouse Models, Goes Public on Shanghai Stock Exchange
GemPharmatech LLC is pleased to announce that on April 25, 2022, its parent company, GemPharmatech Co., Ltd., went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688046. The initial offering included 50,000,000 ordinary shares at a public offering price of￥22.53 ($3.51) per share.
